Equities researchers at HC Wainwright assumed coverage on shares of Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) in a research note issued to investors on Thursday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $5.00 price ta…